---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pharmacodynamics"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pharmacodynamics. Topics: Preclinical intratumoral TGF-beta neutralization and durable response in head and neck xenografts, Plasma TGF-beta1 neutralization by dose in the phase 1 dose escalation, EGFR target saturation inferred from exposure at doses of 500 mg or more, Plasma TGF-beta1 and tumor pSMAD2 in the 1500 mg weekly first-line HNSCC cohort, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Preclinical intratumoral TGF-beta neutralization and durable response in head and neck xenografts

> “TGFβ in tumors was neutralized by approximately 90% in animals dosed with 10 mg/kg of BCA101 compared with 54% in animals dosed with equimolar TGFβRII-Fc.”
> “In patient-derived xenograft mouse models of head and neck squamous cell carcinoma, BCA101 showed durable response after dose cessation.”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

<a id="topic-2.1.2.6.2-2"></a>

### Plasma TGF-beta1 neutralization by dose in the phase 1 dose escalation

> “Patients treated with ficerafusp alfa achieved complete and prolonged neutralization of TGF-β1 in plasma at weekly doses of ≥500 mg (Fig. 3A). Minimal neutralization of TGF-β2 was observed at doses of ≥500 mg (Fig. 3B). TGF-β3 levels were close to the lower limit of quantification and therefore not analyzed.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.2-3"></a>

### EGFR target saturation inferred from exposure at doses of 500 mg or more

> “However, a dose-proportional increase in Cmax and AUC0–168h observed at doses ≥500 mg suggested that EGFR is likely fully saturated at this dose range.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.2-4"></a>

### Plasma TGF-beta1 and tumor pSMAD2 in the 1500 mg weekly first-line HNSCC cohort

> “Complete and prolonged neutralization of TGF-β1 and minimal neutralization of TGF-β2 was observed in plasma after study treatment (Figs 4A and 4B).”
> “TGF-β–dependent pSMAD2 signaling was measured in paired tumor biopsies (baseline and cycle 2 day 1; n = 10). Significant downregulation of pSMAD2 (P < .05) was observed after treatment, particularly in HPV-negative tumors (Fig 4C).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.6.2-5"></a>

### Tumor pSMAD2, CD8 T-cell infiltration, and circulating immune markers across the 750 mg, 1500 mg, and 2000 mg cohorts

> “Consistent with the observed clinical dose-response, biomarker analyses demonstrate a trend toward enhanced localized TGF-β pathway inhibition (measured via pSMAD2 reduction in tumor tissue) at the 1500 mg QW and 2000 mg Q2W dose levels”
> “Further supporting the sustained clinical benefit, this optimized target engagement is accompanied by the upregulation of key circulating immune markers (TNF-α, IFN-γ, CXCL9, and CXCL10), reflecting systemic immune activation at higher doses”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “Sustained TGF-β neutralization in plasma was observed across all dose groups”
> “Increased CD8 T cell tumor infiltration was observed in all dose groups, reaching statistical significance in the 1500 mg QW and 2000 mg Q2W dose groups”

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-2.1.2.6.2-6"></a>

### Company-reported biomarker comparison of 1500 mg and 750 mg weekly

> “In conjunction with the 2025 ESMO Asia Congress, we hosted a corporate call which included new biomarker data demonstrating that that 1500mg of ficerafusp alfa yielded a greater increase in TGF-β inhibition within the tumor microenvironment and greater immune activation, compared to 750mg of ficerafusp alfa.”
> “Updated biomarker results demonstrated that 2000mg Q2W maintains TGF-β inhibition and immune activation while delivering deep responses, consistent with the differentiated clinical profile established by 1500mg QW of ficerafusp alfa.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.6.2-7"></a>

### Pembrolizumab exposure-response

> “There are no clinically significant exposure-response relationships for efficacy or safety at pembrolizumab dosages of 200 mg or 2 mg/kg every 3 weeks and 400 mg every 6 weeks regardless of cancer type”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
